HIV, Gilead and lenacapavir

Every year, my colleagues and I put together a list of what we think are the top 10 breakthrough technologies of that year.
A yearly injection such as Lenacapavir could help overcome barriers to PrEP accessibility by increasing its uptake and making ...
An annual shot to protect against HIV infection has successfully passed an early safety trial, according to research ...
Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.
HIV/AIDS continues to disproportionately affect Black Americans, despite overall progress in reducing infection rates.
HIV self-testing remains underutilized among not only the general public, but especially people who use drugs.
March is a significant month for women's health, observing International Women's Day and National Women's HIV/AIDS Awareness ...
Researchers from the HIV Prevention Trials Network (HPTN) have presented results from the HPTN 094 ("INTEGRA") study at the ...
New real-world and implementation study data highlight the efficacy of ViiV’s long-acting injectables for HIV prevention and ...
A South African Medical Research Council (SAMRC) study has revealed that HIV remains one of the leading causes of death in ...